Quantification of amyloid PET for future clinical use: a state-of-the-art review

HG Pemberton, LE Collij, F Heeman, A Bollack… - European journal of …, 2022 - Springer
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Development of positron emission tomography β-amyloid plaque imaging agents

CA Mathis, NS Mason, BJ Lopresti, WE Klunk - Seminars in nuclear …, 2012 - Elsevier
For 100 years, β-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) have been
recognized as the neuropathological hallmarks of Alzheimer's disease (AD), and their …

Gut microbiome composition may be an indicator of preclinical Alzheimer's disease

AL Ferreiro, JH Choi, J Ryou, EP Newcomer… - Science translational …, 2023 - science.org
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through
preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work …

Regional Aβ-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading

WJ Lee, JA Brown, HR Kim, R La Joie, H Cho, CH Lyoo… - Neuron, 2022 - cell.com
Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer's disease, but it
remains unclear how these proteins interact to promote disease. Here, by combining cross …

Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease

A Moscoso, MJ Grothe, NJ Ashton, TK Karikari… - JAMA …, 2021 - jamanetwork.com
Importance Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as
an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its …

Association between midlife vascular risk factors and estimated brain amyloid deposition

RF Gottesman, ALC Schneider, Y Zhou, J Coresh… - Jama, 2017 - jamanetwork.com
Importance Midlife vascular risk factors have been associated with late-life dementia.
Whether these risk factors directly contribute to brain amyloid deposition is less well …

In vivo staging of regional amyloid deposition

MJ Grothe, H Barthel, J Sepulcre, M Dyrba, O Sabri… - Neurology, 2017 - AAN Enterprises
Objectives: To estimate a regional progression pattern of amyloid deposition from cross-
sectional amyloid-sensitive PET data and evaluate its potential for in vivo staging of an …

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

B Dubois, HH Feldman, C Jacova, H Hampel… - The Lancet …, 2014 - thelancet.com
In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis

G Klein, P Delmar, N Voyle, S Rehal… - Alzheimer's research & …, 2019 - Springer
Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully
human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor …

Cascading network failure across the Alzheimer's disease spectrum

DT Jones, DS Knopman, JL Gunter, J Graff-Radford… - Brain, 2016 - academic.oup.com
Complex biological systems are organized across various spatiotemporal scales with
particular scientific disciplines dedicated to the study of each scale (eg genetics, molecular …